Apimeds Pharmaceuticals US, Inc. filed an amendment on December 10, 2025, to correct clerical errors in their earlier merger agreement and securities purchase agreement from December 1, 2025. The amendment clarifies that the Common Stock Cap is now 0% and the Acquiror Preferred Stock for existing common stock is 90.9%.